Over the last decade there have been numerous publications describing the involvement of transporters in drug disposition. The assignment of drugs as either substrates or inhibitors of transporters has now become commonplace, however the translation of these data into meaningful predictions of either in vivo PK or DDI liability has proved to be more challenging. This presentation will elaborate on the strategy currently utilized at BMS. Namely, to either frontload transporter studies that can help guide the selection of a candidate drug in early discovery or wait till development to conduct studies that only inform on drug labelling. <br/>

Incorporation of transporter data for driving decision making in drug discovery

251st National Meeting (2016)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.